Predictors of latency among patients with t-ALL
| . | No. of patients . | HR (95% CI) . | P . |
|---|---|---|---|
| Prior malignancy | 1.21 (0.76-1.95) | .40 | |
| Hematologic | 44 | ||
| Solid | 72 | ||
| Topoisomerase II inhibitors | .01 | ||
| Yes | 37 | 1.75 (1.05-2.65) | |
| No | 78 | — | |
| Radiotherapy | .30 | ||
| Yes | 64 | 1.25 (0.82-1.92) | |
| No | 51 | — | |
| Immunophenotype | .48 | ||
| B-ALL | 107 | 1.31 (0.61-2.77) | |
| T-ALL | 9 | — | |
| Cytogenetics | 26 | ||
| BCR-ABL | 0.65 (0.40-1.05) | .08 | |
| MLLr | 14 | 4.34 (2.05-9.21) | <.001 |
| MDS-like* | 28 | 1.43 (0.79-2.60) | .23 |
| Other | 9 | 1.29 (0.62-2.68) | .48 |
| Normal | 27 | — |
| . | No. of patients . | HR (95% CI) . | P . |
|---|---|---|---|
| Prior malignancy | 1.21 (0.76-1.95) | .40 | |
| Hematologic | 44 | ||
| Solid | 72 | ||
| Topoisomerase II inhibitors | .01 | ||
| Yes | 37 | 1.75 (1.05-2.65) | |
| No | 78 | — | |
| Radiotherapy | .30 | ||
| Yes | 64 | 1.25 (0.82-1.92) | |
| No | 51 | — | |
| Immunophenotype | .48 | ||
| B-ALL | 107 | 1.31 (0.61-2.77) | |
| T-ALL | 9 | — | |
| Cytogenetics | 26 | ||
| BCR-ABL | 0.65 (0.40-1.05) | .08 | |
| MLLr | 14 | 4.34 (2.05-9.21) | <.001 |
| MDS-like* | 28 | 1.43 (0.79-2.60) | .23 |
| Other | 9 | 1.29 (0.62-2.68) | .48 |
| Normal | 27 | — |
—, the reference group for HR calculation; T-ALL, T-cell ALL.
MDS-like cytogenetic abnormalities included deletions of chromosomes 5, 7, 11, 13, 17, and 20, as well as trisomy 8.